In 16 countries in sub-Saharan Africa, from 5% to 26% of adults aged 15-49 are HIVpositive. Because HIV transmits through memorable sexual or skin-piercing events, researchers working with Africans with new infections should be able to identify the risks that led to their infections and so explain how HIV transmits so extensively in Africa. But that has not happened.
Introduction
Africa's unexplained HIV epidemics: HIV not only infects more adults in sub-Saharan Africa than elsewhere, but also reaches them through a different mix of sexual and blood-borne risks. Only 0.3% (3 in 1,000) of adults are HIV-positive outside Africa compared to 5% in Africa. [1] In most countries outside Africa, the two risks that drive HIV epidemics are anal sex among men who have sex with men (MSM) and blood exposures when injection drug users (IDUs) share syringes and needles. With these risks, infections concentrate in men.
In contrast, HIV in Africa attacks the general population, more women than men are infected, and MSM and IDUs account for small minorities of infections. In the worst epidemics, from 11% to 26% of adults aged 15-49 years are HIV-positive in nine countries in Southern Africa: Botswana, Lesotho, Malawi, Mozambique, Namibia, South Africa, Swaziland, Zambia, and Zimbabwe. [2] [3] [4] In the next six worst epidemics in East and Central Africa, 5%-6.5% of adults are infected in Cameroon, Equatorial Guinea, Gabon, Kenya, Tanzania, and Uganda. [2] These levels of HIV prevalence -as bad as they are -understate lifetime risk. Taking the 5-year age cohort with the highest prevalence in recent national surveys, men"s and/or women"s HIV prevalence peaks over 40% in Swaziland, Botswana, and Lesotho and over 25% in Zimbabwe, South Africa, and Zambia (Table 1) . Even these figures understate lifetime risk by ignoring later infections and early deaths; by age 35, many Africans have already died with AIDS. Moreover, men and women in urban areas are at even higher risk. Because this review focuses on risks for HIV incidence, I exclude two trials that measure success by HIV prevalence [11] [12] [13] and include two that assess success by composite measures of incidence of conventional sexually transmitted infection (STI) with or without HIV, but that also measured HIV incidence. [14] [15] [16] [17] 
Scale and focus of RCTs for HIV prevention among men and women in Africa
This search identified 44 RCTs of interventions to prevent HIV among men and/or women in Africa (see references in Table 2 and the list of RCTs in the Appendix Table) . Trials span nearly a quarter century, with the first initiated in 1987 and the latest stopped in 2011.
For all RCTs, this review extracts available information on numbers of participants in Africa, person-years (PYs) of follow-up, and incident HIV infections (see Table 2 and Appendix Table) . Study teams for 22 RCTs did not report at least some of the basic data summarized in this review; for 18 of these RCTs, I estimate all missing data from other reported data (the Appendix Table identifies these estimates as bolded numbers, and Appendix notes explain the derivation of the estimates). Some trials recruited adults in other countries (the Appendix Table reports study locations); in such cases, this review extracts or estimates data for Africa only. Because it was not possible to estimate participants, PYs, and/or infections for several RCTs, summary data in Table 2 and the Appendix likely underestimate actual totals from 44 RCTs. These 44 trials followed a total of more than 120,000 adults for more than 210,000 PYs and observed more than 4,000 incident (new) infections (Table 2 and Appendix). Women account for 57% of follow-up time and 77% of incident infections.
Twenty-six RCTs recruited men and/or women from the general population (e.g., from rural communities, family planning clinics, and workplaces), accounting for 88% of follow-up time and 79% of incident infections. The study teams for these RCTs had an opportunity to trace the source of incident HIV infections for thousands of adults in the general population with few sexual partners or unusual skin-piercing events; but that did not happen (see below).
Four RCTs that recruited only discordant couples -also from the general populationaccounted for 7% of PYs and infections. These RCTs provide an opportunity to investigate the circumstances that influence sexual transmission, such as high viral load, pregnancy, and coinfections. A minority of incident infections observed in these RCTs did not come from the HIVpositive partner -challenging study teams to identify and trace other sexual and non-sexual risks; but that also did not happen (see below).
Thirteen RCTs followed high risk women (e.g., sex workers, women serving drinks at bars), accounting for 6% of PYs and 13% of infections. Most of these studies tested women every 1-3 months (see Appendix Table) , giving study teams a limited number of skin-piercing events and, for some women, a limited number of unprotected sex partners to identify and investigate; but that also did not happen (see below). The one RCT that followed high risk men (MSM) in Africa and five other countries followed only 88 men in Africa, and has not reported follow-up PYs or infections in Africa.
The types of interventions studied most intensively according to PYs of follow-up are: information, education, and communication (IEC), with 45% of PYs and 23% of infections (including two RCTs that combined STI treatment with IEC); STI treatment, with 44% of PYs and 29% of infections; and vaginal microbicides, with 14% of PYs and 31% of infections.
RCT findings: Interventions' effect on HIV incidence
One important result from these RCTs is the relative risk (RR) for HIV incidence in the intervention vs. the control arm. For example, if 10 of 100 adults in the intervention arm acquire HIV in a year vs.15 of 100 adults in the control arm, the RR for HIV incidence among adults in the intervention vs. the control arm is 0.67 (= [10 per 100 PYs]/[15 per 100 PYs]). But even if an intervention has a low RR, success cannot be credited to the intervention without knowing how adults in both arms acquired HIV, to see whether and how the intervention was the factor that made the difference. Furthermore, the usefulness of interventions with low RRs depends as well on other factors -such as expense and side effects.
Four of 44 RCTs tested two interventions each, [21, 43, 44, 52] giving a total of 48 interventions (Table 3 and Appendix Table) . Study teams reported RRs for HIV incidence in the intervention vs. the control arm for 44 of 48 interventions. Two more RRs can be estimated from reported data (see bolded RRs and explanations in the Appendix). [34, 35, 69, 70] The two missing RRs are from trials that monitored but did not report HIV incidence. [14] [15] [16] [17] (Six RRs reported in Table 3 are from cohorts including adults from Brazil, Ecuador, India, Peru, the US, and/or Thailand; see RRs in italics in the Appendix Table. ) [43, 54, 55, 63, 67] Thirty-six of 46 interventions for which an RR is available had no apparent favorable impact, with RRs not significantly less than one; this includes one RR significantly greater than one (see the paragraph on vaginal microbicides, below). One notable failure was the one vaccine intervention, with RR = 1.25; [31] with no effective vaccine in sight, Africans will have to rely on other strategies to stop HIV for the foreseeable future.
Ten interventions had RRs significantly less than one, which suggests they might be useful for HIV prevention (see Table 3 and underlined RRs in the Appendix Table) . These 10 apparently successful interventions are: five tests of pre-exposure prophylaxis (PrEP) with antiviral drugs; three trials of circumcision to protect men; a trial of STI treatment; and a test of antiretroviral therapy (ART) for HIV-positive persons to protect sexual partners. [23] that reported an RR for women only (the trial observed only five infections in men) and one intervention among discordant couples (circumcising men to protect women). [53] † Two interventions combining STI treatment and IEC are listed in both of these rows.
Researchers have tested more interventions among women than men, but have had more apparent successes among men ( Table 3) . Four of five interventions among men only had RRs significantly less than one (three circumcision trials [32] [33] [34] and one PrEP intervention [55] ). On the other hand, only one of 26 interventions among women had an RR significantly less than one (the trial of PrEP delivered as a vaginal gel [37] ). The other five RRs significantly less than one come from 17 interventions tested among men and women together (three PrEP interventions, [29, 52] and one intervention each of STI treatment [18] and ART as prevention [54] ). (For interventions among men and women together, some study teams have also reported separate RRs for men and for women; see details in the Appendix).
Following paragraphs briefly consider the implications of observed RRs for HIV prevention according to type of intervention.
IEC -eight interventions failed: Without a vaccine, HIV prevention relies heavily on people recognizing and avoiding risks. Thus, the persistent failure of IEC interventions -such as educational events for communities in Uganda [21] and counseling workers to avoid HIV in Zimbabwe [25] -is a serious problem. Lack of impact from IEC may be due to people"s failure to curtail sexual risks. Alternately, it may be due to incomplete IEC messages, which do not alert people to skin-piercing risks. [71, 72] As detailed below, RCTs have not reported enough information about sex partners and skin-piercing events to show why IEC interventions failed.
STI treatment -eight of nine failed, one puzzling success: The first RCT that treated STIs to reduce HIV transmission -in Mwanza, Tanzania, 1991-94 -reported that HIV incidence was 42% lower in communities served by clinics offering improved STI treatment; the RR = 0.58 in this trial was significantly less than 1 (p = 0.007). [18] Eight subsequent trials of STI treatment to reduce HIV incidence reported RRs ranging from 0.7 to 1.53, with a median of 1.04, and with no RR significantly less than one (see references in Table 3 and the Appendix Table) . Considering all RCTs of STI treatment together, there is no reason to expect that improving STI treatment would have an important impact on Africa"s HIV epidemics.
One puzzle posed by these nine RCTs is why the Mwanza trial appears to have been a success. One common explanation is that HIV in Mwanza concentrated in promiscuous adults who were also infected with conventional STI, so that STI treatment could have a big impact on HIV transmission. [73] However, the facts do not agree: In Mwanza"s baseline survey, the 10% of men reporting the most partners in the previous 12 months had only 11% of HIV infections among men; and the 10% of women reporting the most partners had only 18% of women"s infections. [74] Another hypothesis is that the RCT"s provision of syringes, oral antibiotics, and benzathine (long-acting) penicillin to clinics in intervention communities reduced HIV transmission through injections in those communities. [19, 75, 76] Vaginal microbicides -all failed, some badly: Vaginal microbicides have been tested more often than any other intervention -13 RCTs have tested 15 interventions with vaginal microbicides. (In this review, one trial of PrEP delivered as a vaginal gel [37] is discussed with other PrEP trials; see below.) Results with vaginal microbicides have been dismal; RRs range from 0.7 to 1.7, with a median of 1.05, and with no RR significantly less than one. One RR = 1.5 from a trial of nonoxynol-9 gel [63] was significantly greater than one (p = 0.047). Two other trials were stopped early with RRs greater than one that might have become significant if trials had continued. [60, 67] PrEP -six successes, several failures: Beginning in 2004, a series of RCTs have been giving antiviral drugs to HIV-negative people -in daily oral doses or in a vaginal gel before and after coitus -to see if it helps them to resist HIV infection. Trials have used tenofivir disproxil fumarate (TDF) with or without emtricitabine (FTC).
A first trial of oral PrEP with TDF among high risk women in Ghana, Cameroon, and Nigeria, 2004-06, [68] reported an RR = 0.35 (p = 0.24). Although the RR is not significantly less than one, the trial could be considered a success. Public debates about research ethics -including participants" post-trial access to intervention drugs and treatment for those acquiring HIV during the trial [77] -brought the trial to an early end in Cameroon and Nigeria, and likely prevented a significant result. In 2010-11, three RCTs testing oral TDF or TDF/FTC among general population men and women, [29, 30] discordant couples, [52] and high risk men [55] reported four RRs ranging from 0.27 to 0.56, all significantly less than one (see details in the Appendix).
These five successes with oral PrEP came with two failures: In early 2011, a trial of oral TDF/FTC among high risk women in Kenya and Uganda reported no impact on HIV incidence and an unexplained higher rate of pregnancy in the intervention arm. [69, 70] In early fall 2011, managers of a large RCT with parallel tests of oral TDF, oral TDF/FTC, and vaginal gel with TDF among women in three African countries stopped its test of oral TDF after an interim data review determined "the trial will not be able to demonstrate that [TDF] tablets are effective in preventing HIV." [78] (Because the rest of this RCT is continuing, and the study team has not reported infections, PYs, or an RR for the suspended trial of oral TDF, this RCT is not is not included in the Appendix Table or in Tables 2 and 3 in this review.)
In addition, one apparent success with PrEP is difficult to interpret: In 2010, a trial of TDF in a vaginal gel among general population women in South Africa reported an RR = 0.61, significantly less than one (p = 0.017). [37] Although incidence in the intervention arm was lower than in the control arm -5.6 vs. 9.1 per 100 PYs -it was still dangerously and inexplicably high. With incidence as observed in the intervention arm, 44% (=1-[1-0.056] 10 ) of initially HIVnegative women would be HIV-positive in 10 years. Furthermore, if women"s reported average of 12 unprotected coital acts per year is accurate, if 25.8% of partners were HIV-positive (the prevalence among adults in KwaZulu Natal in 2008), [4] and if sex accounts for all infections, then even with the gel the rate of HIV acquisition per unprotected coital act with an HIV-positive partner was 1.8%, [79] far greater than widely cited rates of 0.05% to 0.11%. [80, 81] Considering not only the results from these trials, but also previous experience with antivirals to protect health care workers exposed to HIV through needlestick accidents and to prevent mother-to-child transmission, there is little doubt that PrEP can prevent HIV in some circumstances. But even ignoring several failures of oral PrEP among women and unexplained high incidence with vaginal PrEP, it"s not at all clear how PrEP could have an important impact on Africa"s epidemics. Obstacles to widespread use include cost and potentially dangerous side effects. Where risks are recognized, cheaper and more reliable options such as condoms are often available.
Circumcision to protect men -three successes, continuing controversies: In late 2005, a trial of circumcision to protect men in South Africa reported lower HIV incidence among circumcised vs. intact men, with a significant RR of 0. the study team has not reported this RR, but has reported enough data to calculate it (see the Appendix notes). [34, 35] Based on results from the South African trial (the trial with the lowest RR), circumcision advocates estimate that circumcising all men in Africa by 2015 would reduce new infections by 13% over the next 20 years. [82] Other evidence suggests circumcision would have less impact both on personal risk and on Africa"s epidemics. For example, four other RCTs in this review report HIV incidence in circumcised vs. intact men (excluding the trial among MSM, for which the major risk is receptive anal sex). In three of these trials, HIV incidence in circumcised men ranges from 0.63 to 1.57 times incidence in intact men (none of these differences are significant); the fourth reports no significant difference but does not provide data (Table 4) . Also, national surveys in more than a dozen African countries are almost equally likely to find higher HIV prevalence in circumcised than in intact men. [83] [84] [85] Based on results from the three RCTs of circumcision to protect men reported in 2005-07, WHO and UNAIDS have endorsed circumcision for HIV prevention, [87] and some donors support African governments to circumcise males, including infants. [88] However, the expected impact of mass circumcision on Africa"s HIV epidemics remains controversial. [89] One issue in this controversy is incomplete information about what happened in the trials. Study teams did not collect -or collected but have not reported -relevant information on sexual and blood-borne risks (see below).
Antiretroviral therapy (ART) as prevention -one predictable success: In early 2011, an RCT among HIV discordant couples reported that treating the HIV-positive partner with antiviral drugs reduced HIV transmission to susceptible partners by 96%, giving a significant RR = 0.04 for acquisition of HIV from an HIV-positive partner. This RR increases to 0.11 if one includes HIV acquired from other sources. [54] This result agrees with other studies in Africa and elsewhere that report low rates of sexual transmission from people taking ART and/or with low viral loads. [90] Limits to the extension of this intervention include cost, people not knowing they are infected, and potential harm to HIV-positive adults from beginning ART before it is required for their own health. [91] For people with poor access to more expensive second and third-line drugs, early treatment increases their risk to develop a resistant infection that will not be treated.
RCTs provide little information on HIV risks in Africa
Even when interventions fail, RCTs that can explain why they failed -that identify and report the source of participants" infections -can guide the design of better programs to prevent HIV. Similarly, even when interventions succeed, effective extension may depend on knowing how they succeeded.
All interventions were intended to reduce sexual transmission of HIV. To assess an intervention"s impact on sexual transmission, the study team must know not only HIV incidence in each arm, but also the proportion of infections that come from sex. Suppose, for example, that sex accounts for 1/3rd and blood-borne transmission for 2/3rds of HIV infections. If an IEC intervention warning people about sexual risks for HIV stops half of sexual transmission but has no impact on blood-borne transmission, HIV incidence in the intervention arm would be only 1/6th (1/2 of 1/3 rd ) less than in the control arm. If the study team assumed that all infections came from sex, it would conclude (mistakenly) that the IEC intervention had little or no impact on sexual transmission.
The record of these 44 RCTS in collecting and reporting information to determine the source of observed infections is considered for three basic inquiries: (a) tracing and testing sexual partners of adults who seroconvert; and (b) determining HIV incidence in adults with and without sexual exposures and (c) with and without skin-piercing procedures.
(a) Not tracing sexual partners: Of the 4,029 incident infections recognized in these RCTs, more than 50% were observed in participants followed at intervals no longer than six months (see Appendix Table) . In most trials, large majorities of participants reported not more than one sex partner during follow-up intervals. Yet, no trial determined the HIV status of any sexual partner for any participant with incident infection aside from primary partners (spouses or co-habiting partners) the study team was already following for the same or a related study.
Eleven of 44 RCTs tested and followed the primary partners for some or all participants (Table 5 ). However, five of these 11 studies have not reported what they found. For example, two trials of circumcision to protect men in Uganda [34, 35] were linked to another study that tested and followed more than 1,300 of the men"s partners, [93, 94] but neither circumcision trial has reported the partner"s HIV status for any of the 105 men reported with incident infections. This leaves six RCTs that not only tested some sexual partners but also reported what they found. These six RCTs report HIV-positive partners for a total of 184 men and 199 women with incident infections. But even when a participant with incident HIV has an HIV-positive partner, the partner may not be the source of the participants" infection. Confirming the source of an HIV infection requires sequencing HIV from both parties to see if it is similar.
Four of the six studies that reported HIV-positive partners for participants with incident infections sequenced HIV to see how many infections came from HIV-positive partners. For example, the trial of acyclovir in discordant couples recorded 151 incident infections; sequencing determined that 108 infections came from partners, 40 came from some other source, and three might have come from partners (undetermined linkage). [50] The four studies that sequenced HIV identified a total of 186 participants -90 men and 96 women -who acquired HIV that was similar to HIV from a sexual partner. In other words, only 186 (4.6%) of 4,029 total incident infections observed in 44 RCTs have been reliably traced to a sexual partner. (Studies did not consider the possibility of transmission through razors or other skin-piercing instruments shared among spouses. ) The four RCTs that linked 186 infections to primary partners show nothing very unusual about HIV sexual transmission in Africa. Thus, whatever is different about sexual transmission in Africa -if, indeed, there are differences -would have to involve non-primary partners. Unfortunately, no RCT traced any infections to non-primary partners.
(b) Not asking about or reporting sexual risks: One line of inquiry to investigate the proportion of infections acquired through sex -and thereby to assess an intervention"s success against sexual transmission -is to compare HIV incidence in participants who report possible sexual exposures to HIV (any unprotected sex) vs. HIV incidence in participants who report no possible sexual exposures to HIV (no sex partners or 100% condom use). Whether self-reports can be trusted is another matter; in any case, self-reports should be solicited and reported along with results from other efforts to determine participants" sexual risks.
For most of the RCTs in this review, it"s not clear what information they collected about sexual risks. A complete record of questions asked is available for only four of 44 RCTs: questionnaires for three RCTs coordinated by the US National Institutes of Health"s HIV Prevention Trials Network (HPTN) are available on the web (HPTN 035, [43, 95] HPTN 039, [36, 96] and HPTN 052 [54, 97] ); for a fourth RCT, a journal article details the questions asked. [24] Two of these four studies -trials of vaginal microbicides [43] and acyclovir in women [36] -asked questions to identify participants with no sex partners, [95, 96] but neither reported what they found, and none of the four studies asked questions to determine 100% condom use for all vaginal and anal sex.
For the other 40 RCTs in this review, there is no public record of what the study teams asked aside from the data they report. Reading between the lines, it"s evident many RCTs asked participants if they had any sex partners, and some asked about 100% condom use; for example, several RCTs asked high risk women to maintain daily coital logs. [61, 63] However, only five RCTs (see Table 6 ) report sufficient information from participants" accounts of their sexual risks -any vs. no sex partners or any sex without condoms -to estimate the proportions of observed infections "explained" by sex (statistically linked to sex using standard epidemiological analyses; see notes to Table 6 ). In two of these studies, women who reported one or more partners were counter-intuitively at less risk for HIV than women who reported no partners. In a trial of STI treatment and IEC in Tanzania, 1998-2003, women reporting at least one partner acquired HIV at the rate of 1.2 per 100 PYs (36 cases in 2,975 PYs) vs. 1.6 per 100 PYs for women reporting no partners (12 cases in 770 PYs). [22, 99] Similarly, in the study of PrEP with vaginal gel, women who reported no partners were at greater risk than other women: 20% (one of five) of women who reported no partners acquired HIV vs. 11% (97 of 884) who reported one or more partners. [37] In these two studies, because having a sex partner appeared to reduce women"s risk for HIV, according to standard epidemiological analyses (see notes to Table 6 ), sex explains no infections in women. Abbreviations: see Table 5 . * Participants with incident infections. Note: The percentage of HIV infections statistically linked to any vs. no unprotected sex (i.e., the population attributable fraction [PAF] ) is calculated from the relative risk (RR) and proportion of persons with incident infections exposed to the risk (CE), using the standard formula:
Two of the five RCTs that report participants" accounts of any vs. no sexual risks tested circumcision to protect men in South Africa, 2002-05, and Uganda, 2003-06. In the South African trial, [32] men who reported unprotected sex -at least one sex partner or less than 100% condom use -acquired HIV somewhat faster than men who reported no unprotected sex -1.86 vs. 1.11 per 100 PYs. Using standard epidemiological analyses, the somewhat greater risk for HIV in men reporting unprotected sex explains only 27% of HIV incidence, leaving 73% not explained by sex. Similarly, in the first Ugandan circumcision trial, 2003-06, reporting any vs. no unprotected sex increased men"s risk for HIV by only 1.63 times (RR = 1.63) and explained only 29% of infections. [34] Thus, from the 5 trials that report incident infections in men and/or women with and without unprotected sex, the median percentage of infections explained by self-reported sexual behavior is 28% (see the rightmost column in Table 6 ). Several other RCTs have reported incident infections in adults with no reported sexual risks, but have not given enough information to estimate proportions of infections linked to sex. For example, in the Kenyan circumcision trial, 5 of 7 men infected in the first 1-3 months reported no sex partners during that time [31] ; however, the study has not reported similar information for other men with and without incident infections.
None of the 5 RCTs that reported the data presented in Table 6 accepted their own evidence to conclude that an important proportion of infections may not have come from sex. Instead, study teams proposed "misreporting of sexual behavior" or errors in testing.[p. 144 in reference 99] Thus, the common assertion that all infections are from sex is an assumption (assuming, inter alia, misreports and errors), not an empiric result.
(c) Not asking about or reporting blood-borne risks: Another inquiry to determine the proportions of HIV from sexual and non-sexual risks -and to identify non-sexual risks -is to ask participants at each follow-up visit about skin-piercing events since their last visit. Even when study teams have no interest in blood exposures as risks for HIV, RCTs routinely collect information on participants" instances of ill health (adverse events) and medical care to see if interventions cause health problems. Studies also record procedures administered in study clinics (see, for example, the protocol [100] and forms for collecting and reporting data [101] for the RCT of ART as prevention).
Despite all the information collected on medical procedures, only six of 44 RCTs report data on any medical procedures in participants with and without incident HIV ( Table 7) . Five of Abbreviations: see notes to Tables 5 and 6 . Note: Percentages of HIV infections associated with (statistically linked to) medical procedures are calculated from reported data as explained in the note to Table 6 . these six report data on injections (all injections or injections for particular reasons or in specific facilities). Using standard epidemiological analyses, injections explain a median of 22% (ranging from 0% to 77%) of incident infections in men or women in these five studies (in two studies this statistic is approximated by adding percentages of HIV explained by injections in different facilities). For example, in an RCT of STI treatment in Tanzania, 1991-94, men reporting any vs. no injections in a hospital/clinic or elsewhere were more likely to acquire HIV than other men, and 27% (21% + 6%) of HIV incidence was explained by (statistically linked to) injections. [19, 102, 103] Among women in the same study, 25% of HIV was statistically linked to injections. Similarly, a trial of metrodinazole vaginal gel in Malawi, 2003-05, reported that women receiving hormone injections for birth control were 10.4 times more likely than other women to become HIV-positive. [40] With standard epidemiological analyses, injections explained 77% of HIV infections observed in the study. This statistical link between injections and HIV may be due to injections transmitting HIV or to other risks related to the injections -such as injected progesterone thinning the vaginal wall and increasing women"s susceptibility to HIV from sexual partners. [106] The study team did not test these and other hypotheses by tracing and testing women"s sexual partners and blood contacts, leaving uncertainties about women"s risks for HIV.
One RCT reported HIV infections in women with and without transfusions. Transfusions increased their risk for HIV but, because few women were transfused, appeared to explain only 1.2% of infections.
The South African circumcision trial reported HIV incidence in men with and without a composite measure of health care exposures (having been transfused, injected, or hospitalized). Men with this risk were 1.7 times more likely to acquire HIV than other men. [105] The study also reported that men who visited a clinic for a genital condition were 5.73 times more likely to acquire HIV than other men [32] ; this statistic may point to sexual risks, clinic risks, or genital symptoms due to primary HIV infection from any source.
Despite their own reported evidence, none of the study teams concluded that injections or other skin-piercing procedures accounted for any HIV infections.
Review findings: RCTs raise ethical issues
Some of the RCTs considered in this review demonstrate a double standard between what can be done in countries that fund these studies, and what study teams do in Africa. The ethical issues involved in these differential practices are controversial. The following comments present a brief introduction to selected issues only (Table 8) .
Not telling participants they are HIV-positive: In 1988, the US Office for Protection from Research Risks established the policy that "Individuals may not be given the option "not to know" the result" of their HIV test. [113] At least 14 RCTs in this review enrolled and followed adults without telling some or all their HIV status at baseline or later (Table 8) . If participants asked, some studies would tell, while others sent them to testing services. For example, "Where participants [in an RCT in Tanzania in 1998-2003] indicate that they would like to be advised as to their own HIV-1 serostatus, appointments will be arranged for them to visit a local clinic where a free counselling and testing service will be made available" [Protocol S1, p. 6, in reference 22]. Over time, more RCTs insisted on telling participants their test results. For example, "willing to receive HIV results" was an inclusion criteria for participants in the trial of circumcision to protect men in Uganda, 2003-06, which was funded by the US government. [114] However, the same study team recruited men who did not want to hear the results of their HIV into a parallel trial funded by the Bill and Melinda Gates Foundation. [35, 94] Not warning participants their partners are HIV-positive: US law requires states receiving federal funds for specific health programs to ensure that "a good faith effort be made to notify a spouse of a known HIV-infected patient that such spouse might have been exposed to the human immunodeficiency virus." [115] At least six RCTs in this review followed adults who did not know they were HIV-positive and their HIV-negative partners who did not know they were at risk (Table 8 ). In 2000, the editor of the New England Journal of Medicine criticized one of these six RCTs for not warning spouses at risk, noting that "such a study could not have been performed in the United States"[p. 967 of reference 116]. The study team explained, "this was a community-based trial that enrolled all consenting adults, the identification of couples…was done only retrospectively"[p. 922 of reference 48]. Several years later, three studies in the same community recruited and followed HIV-positive and HIV-negative adults and partners to study the impact of circumcision on sexual transmission of HIV and STIs. [34, 35, 53, 93, 94] One of these studies insisted that men receive their HIV test results; otherwise, studies encouraged [117] but did not insist that participants receive their test results and share them with their partners.
Not telling pregnant and breastfeeding women they are HIV-positive: At least three RCTs did not tell seroconverting pregnant and lactating women they were infected. Related studies later tracked at least some of the children to determine HIV infections and/or mortality (see references in Table 8) .
Not warning partners when participants seroconvert: Many RCTs in this review did not tell participants with incident infections they were infected, while others told them and offered or referred them to counseling. Based on practices common in Africa, counselors would not insist that participants warn their partners, and would not warn partners if participants did not. Thus, most RCTs in this review made no to modest efforts to ensure that partners of participants with new HIV infections were aware of their risk.
Not reporting and investigating unanticipated problems: To protect research participants, study teams are ethically obligated (and often legally obligated in the funding country, even for participants in Africa) to investigate participants" "unanticipated problems" that appear to be linked to their participation in research. [118] Several of 44 RCTS in this review report incident HIV infections that could be considered to be "unanticipated problems" linked to study procedures. For example, an RCT in Malawi reported that women receiving hormone injections had a 10.4 times greater risk to acquire HIV infection compared to other women (see Table 7 ); [40] available information suggests the study clinic administered some if not all these injections [see the trial protocol, supporting information in reference 41]. Similarly, the Kenyan circumcision trial reported HIV infections in four men one month after circumcisions provided by the trial; three of the men reported no sex partners during that month. [33] There is no evidence either study team reported or investigated these infections as unanticipated problems.
Conclusions and recommendations
Conclusion 1: Study teams learned almost nothing about the source of men"s and women"s HIV infections despite recognizing more than 4,000 incident infections, including more than 2,000 in adults retested at intervals of 1-6 months only. Had study teams comprehensively asked about sexual and blood exposures and traced and tested sexual partners, they would likely have found and explained what is different about HIV transmission in Africa. [8] Study teams further weakened the scientific process by not putting their collected data into the public domain, allowing others to review and extend analyses. [119, 120] Failure to ask, trace, and report wasted not only money and time, but also the good faith and misfortune of participants who acquired HIV infections.
Conclusion 2:
No RCT has identified an intervention suitable to be extended into largescale HIV prevention programs. All apparently successful interventions -with RRs significantly less than one -have serious drawbacks. Circumcision is less reliable than other options, expensive, and dangerous; its projected impact on Africa"s epidemics is further clouded by unreported evidence from influential trials and conflicting evidence from other studies (nevertheless, some governments and donors are extending circumcision). PrEP with the drugs used in these RCTs is expensive, has serious side effects, and is less reliable than other options. ART as prevention is expensive and is not without risks for people beginning ART early.
Conclusion 3: Scientific failures are linked to ethical failures. Researchers who did not tell participants when they seroconverted and trace, test, and warn spouses and other sexual partners were not challenged to explain HIV incidence to participants with no sexual exposures to HIV.
Conclusion 4: Scientific and ethical failures are systemic. International and foreign government and private organizations funding the 44 RCTs in this review have for decades supported and accepted the weak research and ethical lapses described in conclusions 1 and 3.
These conclusions lead to four recommendations. Recommendation 1: Governments of countries that host research should insist that studies conform to ethical standards in the funding country, along with any additional standards imposed by the host government. This means, inter alia, that studies should enroll only people who agree to hear their test results -at baseline and during follow-up -and to share an HIVpositive result with their partner.
Recommendation 2: Governments of countries that host research should insist that studies of risks for HIV incidence are scientifically sound. Specifically, governments should insist that study teams: (a) publicly post questionnaires before the study begins; (b) ask not only about sex but also about skin-piercing health care and cosmetic procedures; and (c) for all incident infections, trace and test sexual partners and possible blood contacts. Such research could be expected to produce good information about risks within 1-2 years. And to ensure that study teams do a good job, governments should insist that they (d) post data for public access within a year after data collection is complete.
Recommendation 3: African governments should, as a high priority and with their own funds if necessary, arrange for researchers to revisit completed RCTs to gather additional information, including: offering HIV tests and counseling to seroconverting participants who were not already told they seroconverted; searching for the sources of all incident infections by tracing and testing sexual partners (with participants" permission) and possible blood contacts; and sequencing HIV from participants, partners, and blood contacts to determine epidemiologic linkages.
Recommendation 4: African governments should reestablish HIV prevention efforts on better evidence about risks (see recommendations 1-3 above) fully reported to the public, giving people what they need to make informed personal decisions. This means, in part, warning the public about HIV from skin-piercing events; across Africa, HIV prevalence is lower in countries where more people are aware of blood-borne risks. [121] This also means, for example, warning people that hormone injections for birth control may increase women"s risks both to acquire and to transmit HIV. [122] Similarly, African governments should suspend support for adult male circumcision until study teams for the circumcision trials [32] [33] [34] [35] 53 ] report all collected information, including the HIV-status of sexual partners, blood exposures, and sexual behavior; that would help men make informed decisions. As for infant circumcision for HIV prevention, it cannot be evidence-based, because no one knows what the situation will be in 15 years; it"s a statement of despair to propose that today"s infants will be facing the same HIV epidemics when they become sexually active.
Appendix: Relative risks, numbers of participants followed, person-years of follow-up time, and incident infections for 44 RCTs
All numbers not in bold in the Appendix Table are taken from articles referenced in the first column. Number of participants is the number tested at least once during follow-up, or if that is not available the number entering follow-up. Some study teams reported different data in different reports; in such cases, I chose the most comprehensive data; for example, in the study of acyclovir in discordant couples, [49] [50] [51] I include incident infections during pregnancy, when women were off the study drug. Numbers in bold are estimated from reported data, as explained in notes following the Appendix Table. Appendix Appendix notes: derivation of estimates in the Appendix Table and text Table 5 General population men and women, STI treatment Numbers in bold in the Appendix Table are estimated from reported data as explained in the following notes. Studies for which data has been estimated are listed below in the same order and with the same identifiers as in the Table. Improved treatment, Tanzania, 1991-94 [18, 19] : Number of HIV-negative men and women followed are estimated as 48% and 52%, respectively, of HIV-negative adults followed from the reported proportions of men and women among all HIV-negative and HIV-positive adults followed. PYs is estimated by multiplying number followed by 2 years [p 532 in reference 18] .
Mass treatment, Uganda, 1994-98[20,48,92] : The study team reports that 42 of 46 participants with incident infections and HIV-positive partners had acquired their partners" HIV [92] , but does not specify the sex of those with incident, linked infections. I estimate 21 men and 21 women with incident, linked infections, based on an earlier report that shows a roughly similar number of incident infections in men and women in discordant couples. [48] Improved treatment, Uganda, 1994 Uganda, -2000 : Numbers of men and women followed, men"s and women"s PYs, and incident cases in men and women are estimated as 45.5% and 54.5%, respectively, of reported totals for all adults from the reported proportions of men and women in the recruited cohort of HIV-positive and HIV-negative adults [pp. 648-649 in reference 20] .
Improved treatment, IEC, Zimbabwe, 1998 Zimbabwe, -2003 : Numbers of men and women followed are estimated from reported total follow-up time for all HIV-positive and HIV-negative men and women, assuming average follow-up time of 3 years, based on reported median followup time for all adults of 2.9 and 3.0 years in the intervention and control communities, respectively [pp. 549, 554 of reference 22].
General population men and women, IEC
School-based, Tanzania, 1998 Tanzania, -2002 : PYs of follow-up in men and women in each arm are estimated from reported cases and incidence rates for men and women in each arm [p.
of reference 23].
Credit, community-based, South Africa, 2001-05 [24] : Numbers of men and women followed are estimated as 44% and 56% of adults followed, respectively, from women"s proportion of the recruited cohort. PYs are estimated from the reported 3.1 years average followup. Men"s and women"s incident infections are estimated from the reported 142 infections among all adults, assuming that women"s rate of incidence is 2.6 times men"s rate, which is the ratio of reported baseline prevalence in women vs. men [pp. 1978-1980 [25] : Numbers of men and women and PYs followed are calculated as 88.4% and 11.6%, respectively, of participants in the control arm, and 90.5% and 9.5%, respectively, of participants in the intervention arm. Number of incident infections for men and women are estimated from totals for all adults and the report that men"s incidence rate was 1.73 greater than women"s [pp 486-487 in reference 25].
Stepping Stones, South Africa, 2003 Africa, -2006 : PYs of follow-up and incidence rate are estimated from men"s and women"s reported cases and incidence rates in each arm [p 7 in reference 26]. The RR for men and women is from Michielsen [p. 1200 in reference 27].
Cash for no HIV, MW, 2006-08[28]:
The RR is estimated from the reported coefficient of 0.001 for the intervention"s impact on HIV status [ Table 5 of reference 28]. Numbers of men and women followed are estimated from the reported 1,312 men and women recruited, of which and 45% and 55%, respectively, were men and women, 9% were HIV-positive, and 89% were followed. PYs followed is estimated from the reported 2 years of follow-up multiplied by the estimated number of HIV-negative men and women followed. STI, TZ, 2009-10[16,17] : Number of HIV-negative men followed is estimated from the reported 1,198 men followed, less 2.45% HIV-positive men; number of HIVnegative women followed is estimated from the reported 1,221 women followed, less 4.63% that were HIV-positive [16] . PYs followed are estimated from the reported 1 year follow-up with the intervention, assuming that 90% are followed (cf: 92.2% received their test results after several weeks). [16] These estimates do not include 1 year of follow-up after the end of the intervention.
Cash for no

General population men and women, vaccine
Vaccine, SA, 2007-09 [31] : Total follow-up time for men and women combined is estimated as the sum of follow-up times in the intervention and control arms, which are estimated from 34 and 28 reported infections in the intervention and control arms, respectively, and incidence rates of 4.54 and 3.70 per 100 PYs in the intervention and control arms, respectively. Follow-up time for men and women are estimated as 45% and 55%, respectively, of estimated total follow-up time from the reported percentage of men among participants. [34] General population women, microbicides (except PrEP) PC-515, SA, 1999 : PYs of follow-up is estimated from reported cases and incidence rates in each arm. The incidence rate in the combined arms is estimated from reported cases and estimated total PYs of follow-up. [52] : Numbers of men and women followed are calculated from men"s and women"s reported 62% and 38%, respectively, of the total 4,747 participants. Men"s and women"s PYs of follow-up are estimated as 63% and 37%, respectively, of the reported 7,337 total PYs, allowing some women"s follow-up time lost to pregnancy. [67] : PYs of follow-up for all women is estimated from reported total incident infections and incidence rates in each arm. PYs of followup for African women is estimated from the report that 80.5% of women followed were African, assuming that percentage holds for follow-up time as well. Incidence rate for African women is estimated from estimated PYs and reported incident infections in African women.
High risk women, PrEP
Oral TDF/FTC: KY, SA, TZ, 2009-11 [69, 70 ] RR = 1 is estimated from a preliminary report of no difference between study arms; number of women followed is estimated from the reported 1,951 women enrolled. [69] PYs of follow-up is estimated from the reported 56 incident infections and 5% per year incidence rate. [69] 
